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Abstract
Introduction: Several national and regional central line-associated bloodstream infections (CLABSI) surveillance programs
do not require continuous hospital participation. We evaluated the effect of different hospital participation requirements on
the validity of annual CLABSI incidence rate benchmarks for intensive care units (ICUs).
Methods: We estimated the annual pooled CLABSI incidence rates for both a real regional (,100 ICUs) and a simulated
national (600 ICUs) surveillance program, which were used as a reference for the simulations. We simulated scenarios where
the annual surveillance participation was randomly or non-randomly reduced. Each scenario’s annual pooled CLABSI
incidence rate was estimated and compared to the reference rates in terms of validity, bias, and proportion of simulation
iterations that presented valid estimates (ideal if$90%).
Results: All random scenarios generated valid CLABSI incidence rates estimates (bias 20.37 to 0.07 CLABSI/1000 CVC-days),
while non-random scenarios presented a wide range of valid estimates (0 to 100%) and higher bias (22.18 to 1.27 CLABSI/
1000 CVC-days). In random scenarios, the higher the number of participating ICUs, the shorter the participation required to
generate $90% valid replicates. While participation requirements in a countrywide program ranged from 3 to 13
surveillance blocks (1 block=28 days), requirements for a regional program ranged from 9 to 13 blocks.
Conclusions: Based on the results of our model of national CLABSI reporting, the shortening of participation requirements
may be suitable for nationwide ICU CLABSI surveillance programs if participation months are randomly chosen. However,
our regional models showed that regional programs should opt for continuous participation to avoid biased benchmarks.
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Introduction
Central line-associated bloodstream infections (CLABSI) are
associated with an important burden of illness in intensive care
units (ICUs).[1] National and regional surveillance programs are
essential to provide information on ICU CLABSI epidemiology
and on changes in trends over time. Furthermore, surveillance
results are used for the planning and evaluation of infection
control measures, as well as for the generation of benchmarks.
Despite their importance, national and regional surveillance
programs face significant challenges when recruiting participating
hospitals. Several hospitals cite limited resources for performing
continuous surveillance as the reason for not participating in such
programs.
Consequently, many national and regional ICU CLABSI
surveillance programs have eliminated the continuous participa-
tion requirement from their protocols. For example, the National
Healthcare Safety Network (NHSN) in the U.S. requires ICUs to
participate a minimum of 1 month/year, while in England the
cut-off is 3 months/year.[2,3] In the Netherlands, hospitals
participate at their own discretion in the national surveillance
program.[4,5].
Reducing the annual hospital participation in surveillance
programs raises concerns about the validity of the obtained
benchmarks, as the aforementioned cut-offs are arbitrary and
variable. Furthermore, no study has yet evaluated the minimum
number of months ICUs must participate in a national or a
regional surveillance program to generate valid benchmarks for
annual pooled CLABSI incidence rates. Thus, the purpose of this
study was to determine, through simulation, the impact of different
participation requirements on the ability of countrywide and
regional surveillance programs to yield valid estimates of the true
annual ICU pooled CLABSI incidence rates.
Methods
This study was approved by the McGill University Institutional
Review Board and the need for informed consent was waived.
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To answer our research question at a national level, we
simulated a database of a countrywide ICU CLABSI surveillance
program containing 600 ICUs (480 adult units, 48 pediatric ICUs
– PICUs -, and 72 neonatal ICUs – NICUs -; 60% teaching units)
that continuously participated in the program during one year. We
used published data from NHSN to model the ICU population
structure (type of ICU and academic profile), and data from the
Surveillance Provinciale des Infections Nosocomiales (SPIN)
program, an ICU CLABSI surveillance program in the province
of Quebec, Canada, to model the variables used for the calculation
of CLABSI incidence rate (CLABSI cases – numerator - and
central venous catheter-days – CVC-days, denominator) per
participating ICU and for each of the 13 28-day surveillance
blocks/year.[6,7,8,9,10,11] A detailed explanation of the simula-
tion model can be found in Appendix S1.
The simulation model used to create the national database was
run 1000 times. This generated 1000 independent and complete
databases, i.e. without missing data. For the purpose of this study,
we took a random subset of 100 national simulated databases upon
which we performed our statistical analyses.
We also used the SPIN database to determine the effect of
different participation requirements at a regional level. We initially
built a dataset with no missing values including 44 ICUs (34 adult
ICUs, 4 PICUs, and 6 NICUs) that continuously participated in
the SPIN program during 2007–2008 (complete dataset I).[6]
Variables contained in this dataset were: type of ICU, academic
profile, and number of CLABSI cases and CVC-days per
surveillance period for each ICU (13 blocks/year). To check the
reliability of our results, we built a second regional database, which
included 53 ICUs (43 adult ICUs, 4 PICUs, and 6 NICUs) that
continuously sent data to SPIN during 2008–2009 (complete
dataset II).
Calculation of the reference annual ICU pooled CLABSI
incidence rates
We calculated the annual ICU pooled CLABSI incidence rate
for adult, pediatric, and neonatal ICUs for all national (100) and
regional (2) complete databases, using the following formula:[12]
Annual ICU pooled CLABSI incidence rate~
X
annual CLABSI cases=
X
annual CVC{days
  
 1000
These rates were considered the ‘‘reference rates’’ for each
database because they were calculated using 100% of the data. We
then calculated intervals which limits were values 10% above and
below the annual reference rates.
Simulation scenarios for different length of participation
The complete national and regional datasets were used as the
starting point for the creation of scenarios where the duration of
ICU participation in the surveillance programs was progressively
shortened. To do so, data were either randomly or non-randomly
removed.
1. Random removal of data – equal participation
scenarios. In these scenarios, we simulated a situation where
the surveillance program determined the ICU participation length
per year, making all units participate for an equal number of
blocks, but allowing ICUs to choose, in advance, when (i.e., in
which blocks) data would be collected. We assumed that ICUs’
choice of when to collect data was made in an independent and
random way.
We started by generating a scenario where each ICU submitted
data (i.e., number of CLABSI and CVC-days) for the entire year
except for 1 block that was randomly chosen out of the 13 blocks.
We progressively removed data from 1 additional random block
per ICU until we reached 12 random blocks of missing data.
2. Random removal of data – unequal participation
scenarios. In these scenarios, we simulated the approach
currently used by many surveillance programs. The minimal
required ICU participation per year was set; however, units could
choose to participate for more than the minimum and could
decide during which blocks data would be collected. For the
purpose of this study, the minimal participation was defined as 1
block/year. Again, we assumed that ICUs chose the surveillance
blocks in an independent and random way.
First, we created a scenario where the total ICU population had
an average participation of 12 surveillance blocks/year. We
progressively decreased the average participation 1 block at a time,
until we reached an average participation of 1 block. Blocks were
randomly removed.
The generation of the equal and unequal participation scenarios
was repeated 1000 times per scenario for all national and regional
databases. Adult, pediatric, and neonatal ICU annual pooled
CLABSI incidence rates were calculated for each iteration. We
then built a distribution of the 1000 CLABSI incidence rate
estimates (for adult, pediatric, and neonatal ICUs) for each
complete database and calculated their expected means
The expected means calculated for the random scenarios using
the regional databases were directly compared to the ‘‘reference
rates’’. For the random scenarios involving the national surveil-
lance program, we first built distributions of the expected means
for adult, pediatric, and neonatal ICUs calculated for each of the
100 national databases. Subsequently, we took the means of these
distributions and compared them to their respective ‘‘reference
rates’’.
3. Non-random removal of surveillance periods. These
scenarios examined a situation where the surveillance program
would determine not only the yearly ICUs’ length of participation,
but also when data should be collected. The options in which
surveillance lasted 9, 6, and 3 blocks/year were evaluated. We
investigated 4 different alternatives for when data were required to
be collected: 1) continuous data collection for the first 9, 6, or 3
blocks, 2) the last 9, 6, or 3 blocks, 3) the 9, 6, or 3 middle blocks,
and 4) alternated data collection for a total of 9, 6, or 3 blocks.
Adult, pediatric, and neonatal ICU annual pooled CLABSI
incidence rates were estimated for all 12 scenarios.
The annual pooled CLABSI incidence rate estimates generated
for the regional surveillance program were directly compared to
the ‘‘reference rates’’. For the non-random scenarios involving the
national surveillance program, we calculated the mean of the 100
adult, pediatric, and neonatal estimates and compared them to
their respective ‘‘reference rates’’.
Simulation outcomes
Our primary outcome was defined as the validity of the
estimates of adult, pediatric, and neonatal annual ICU pooled
CLABSI incidence rates for a regional and a national surveillance
program (see ‘‘Statistical comparisons’’). An estimate was consid-
ered valid if it was within 10% of the ‘‘reference rate’’. As
secondary outcomes, we evaluated the estimated average bias and
the proportion of valid simulated iterations.
Statistical comparisons
All simulations were performed using R 2.11.0. The perfor-
mance of our model used to simulate the national surveillance
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mean square error.[13,14] To do so, we compared the mean
simulated adult, pediatric, and neonatal ICU pooled CLABSI
incidence rates to the SPIN adult, pediatric, and neonatal ICU
pooled CLABSI incidence rates for 2007–2009.
The comparison between the estimates of the annual ICU
pooled CLABSI incidence rates and the ‘‘reference rates’’ was
performed in 3 ways:[15]
1. Validity: an estimate, including the expected mean calculated
for the random data removal scenarios, was considered to be
valid if it was within 10% of the ‘‘reference rate’’. The 10%
range was determined based on a consensus among infection
control experts.
2. Average bias: calculated by subtracting the expected mean of
the estimate from the ‘‘reference rate’’.
3. Proportion of iterations whose annual ICU CLABSI pooled
incidence rate estimates were valid: exclusive to the random
data removal scenarios. A scenario was considered acceptable if
the estimated rate was valid, i.e., was within 10% of the true
rate, in at least 90% of the iterations.
Results
Performance of the model used to simulate the national
surveillance program database
Estimation of the adult, pediatric, and neonatal annual ICU
pooled CLABSI incidence rates presented bias of 20.23, 20.05,
and 20.33 CLABSI/1000 CVC-days, respectively. The maxi-
mum amount of bias (NICU) represented a decrease of 6.6% of
the true CLABSI incidence rate and was considered acceptable.
Adult, pediatric, and neonatal ICU CLABSI incidence rates
presented random mean square errors of 0.053, 0.119, and 0.240,
respectively.
Calculation of ‘‘reference rates’’
Estimated ‘‘reference rates’’ rates for adult, pediatric, and
neonatal ICUs using the simulated national database were 1.52,
2.13, and 4.67 CLABSI/1000 CVC-days, respectively. ‘‘Refer-
ence rates’’ for adult, pediatric, and neonatal ICUs at a regional
level were 1.83, 2.79, and 5.69 CLABSI/1000 CVC-days for
2007–2008, respectively. For the 2008–2009 periods, ‘‘reference
rates’’ were 1.68 CLABSI/1000 CVC-days (adult ICUs), 1.52
CLABSI/1000 CVC-days (PICUs), and 4.18 CLABSI/1000
CVC-days (NICUs).
Random scenarios with equal ICU participation
At a national level, all scenarios presented valid estimates for all
annual ICU pooled CLABSI incidence rates (bias 20.0091 to
0.0119 CLABSI/1000 CVC-days – Table 1). The minimum
participation required for adult ICUs to yield 90% of valid
iterations was 3 surveillance blocks, while PICUs and NICUs
required participation during the entire surveillance year (13
blocks).
Similarly, all scenarios presented valid estimates for all annual
ICU pooled CLABSI incidence rates at a regional level, but with
considerably higher bias (20.1782 to 0.0352 CLABSI/1000
CVC-days – Table 1). In addition, to yield 90% of valid iterations,
the minimum participation required for adult ICUs was longer
than at the national level (9 to 10 blocks), while the required
participation for neonatal and pediatric ICUs was 9 and 12 to 13
blocks, respectively.
Random scenarios with unequal ICU participation
Valid estimates of all annual ICU pooled CLABSI incidence
rates were obtained in all scenarios (bias 20.0168 to 0.0054
CLABSI/1000 CVC-days –Table 1) at a national level. The
average length of participation to obtain 90% of valid iterations
was 3, 12, and 8 surveillance blocks for adult, pediatric, and
neonatal ICUs, respectively.
At a regional level, valid estimates for all ICU CLABSI
incidence rates were also obtained in all scenarios (bias 20.3745 to
0.0743 CLABSI/1000 CVC-days – Table 1). The average
participation requirements for achieving 90% of valid iterations
were longer for all types of ICUs (9 to 10 blocks for adult units, 13
blocks for PICUs, and 12 blocks for NICUs).
Non-random scenarios
When using the national simulated database, the non-random
scenarios that evaluated a total surveillance duration of 9 blocks
per year generated estimates for adult ICU annual CLABSI
pooled incidence rate that were valid for 100% of the sample of
100 simulated databases, while proportions of valid NICU and
PICU estimates between 96 to 98%, and 68 to 78%, respectively.
Overall, bias ranged from 20.0301 to 0.0337 CLABSI/1000
CVC-days (Figure 1). At a regional level, estimates of adult and
neonatal ICU annual CLABSI pooled incidence rates were valid
$80% of the time during the 2007–2009 period. PICUs presented
the worst results, with only 40% (2007–2008) and 20% (2008–
2009) of valid estimates. Overall bias was higher, ranging between
21.2291 and 0.6381 CLABSI/1000 CVC-days (Figure 1).
At a national level, scenarios in which surveillance lasted 6
blocks had 100% of estimates that were valid for adult ICU annual
CLABSI pooled incidence rate, while NICUs presented propor-
tions that varied from 84 to 92% (overall bias 20.035 to 0.015
CLABSI/1000 CVC-days). Less than 53% of PICUs estimates
were valid, with much more prominent bias (21.583 to 0.070
CLABSI/1000 CVC-days – Figure 1). When we calculated
estimates using the regional database (bias from 21.9026 to
1.2666 CLABSI/1000 CVC-days – Figure 1), between 71%
(2007–2008) and 86% (2008–2009) of estimates were valid for
adult ICU annual CLABSI pooled incidence rates, while NICUs
and PICUs presented validity proportions that were 43% (2007–
2008) and 57% (2008–2009), and 43% (2007–2008) and 0%
(2008–2009), respectively.
Finally, scenarios evaluating 3-block surveillance duration had
the worst overall performance at both the national and regional
levels. For national databases, while estimates for adult ICU
annual CLABSI pooled incidence rate produced validity propor-
tions of 97 to 99% and minimal bias (20.0080 to 0.0068
CLABSI/1000 CVC-days), estimates for NICU and PICU were
valid in 65 to 70% and 0 to 37% of cases, respectively, with bias
between 20.0958 and 0.1118 CLABSI/1000 CVC-days
(Figure 1). At a regional level, while the proportions of valid
estimates for NICU annual CLABSI pooled incidence rate were
40% (2007–2008) and 60% (2008–2009), PICUs could not achieve
valid estimates (0%) in any of the two years, and adult ICUs
presented 40% of valid estimates during 2008–2009 and 0%
during 2007–2008. Overall bias ranged between 22.1752 and
3.4614 CLABSI/1000 CVC-days (Figure 1).
Discussion
Our study simulated the effect of different participation lengths
on the validity of national and regional benchmarks for ICU
annual CLABSI pooled incidence rates and demonstrated that
surveillance programs should base their minimum participation
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collected for random intervals during the year, it is possible to
generate valid estimates of the true CLABSI incidence rates using
less data. Nevertheless, this will only be achieved if a surveillance
program has a high number of participating ICUs, as is the case
for countrywide surveillance programs.
Our approach was to use all available data for the calculation of
the annual CLABSI incidence rates, which is similar to what is
currently done by regional and national surveillance programs
worldwide. In our random scenarios, we assumed ICUs randomly
chose when to collect data, something that may be achieved by
asking units to determine a priori when data will be submitted to
surveillance programs; e.g., before each surveillance block. In
using this strategy, missing completely at random data were
produced by design, which allowed the calculation of unbiased
estimates of the annual ICU CLABSI pooled incidence
rates.[14,16,17] However, as the estimates were calculated based
on a lower number of observations, there was a loss in precision,
which could be partially compensated for by either longer
participation or a higher number of participants.
Based on our results, we recommend to maintain the
requirement for continuous participation for small (,100 ICUs)
CLABSI surveillance programs, i.e., regional programs, due to the
limited number of participating ICUs. The elimination of
continuous participation seems only suitable for national pro-
grams, with enough participating units to compensate for the
reduction in surveillance duration. However, even national
programs should be careful when doing so, as further stratification
of CLABSI rates according to ICU types (e.g., adult cardiac or
adult burn units), would cause a substantial decrease in sample size
for incidence rate calculation, thereby threatening benchmark
validity. This problem was exemplified by the lower precision and
validity of PICU and NICU estimates compared to adult ICUs’,
which was driven not by different patient characteristics, but by
the small number of participating units.
CLABSI incidence rates are assumed to vary randomly over the
year, without a seasonal pattern.[18] Thus, as the monthly
CLABSI incidence rate pattern may change over the years, it
becomes problematic for surveillance programs to impose when
participants should collect data. As shown in our non-random
simulation scenarios for a regional surveillance program, options
that worked relatively well in 2007–2008 did not have the same
performance in 2008–2009 and vice-versa. Moreover, the validity
of the results of non-random scenarios also seemed to be associated
with sample size. Yet, despite presenting better results when used
for the larger national surveillance program dataset, non-random
strategy results were more unstable overall when compared to
those produced by random scenarios. Therefore, we do not
recommend the use of this strategy in either small or large
surveillance programs.
Despite the fact that, according to our simulation models, the
continuity of data collection might not be a prerequisite to obtain
valid benchmarks at a countrywide level, we strongly advocate for
continuous CLABSI surveillance throughout the year in all
hospitals. At the hospital-level, annual CLABSI rates are very
unstable because of the small number of CLABSI events and
CVC-days. Therefore, missing 1 or 2 months of data can have a
substantial impact on the annual rate, and cause important bias. In
addition, one of the reasons for doing surveillance is to ensure the
detection of outbreaks, something that is only achieved if rates are
monitored in a continuous fashion.
This study’s major limitation was the non-existence of a national
CLABSI surveillance database where ICUs continuously partic-
ipate throughout the year, as this forced us to simulate such a
dataset. The use of the SPIN database to model the expected
number of ICU CLABSI and CVC-days decreased the precision
of our simulated results for PICUs and NICUs as shown by the
Table 1. Results of random data removal scenarios.
Scenario Number of ICUs Validity (%)
Average bias (per 1000
CVC-days)
Participation to reach 90% cut-off
(surveillance blocks)
Equal participation
National
Adult ICUs 480 100 20.0005 to 0.0004 3
PICUs 48 100 20.0091 to 0.0105 13
NICUs 72 100 20.0034 to 0.0119 13
Regional
Adult ICUs 43 100 20.0146 to 0.0213 9
PICUs 4 100 20.1782 to 0.0186 12 (2007–2008) and 13 (2008–2009)
NICUs 6 100 20.1387 to 0.0352 10
Unequal participation
National
Adult ICUs 480 100 20.0003 to 0.0023 3
PICUs 48 100 20.0168 to 0.0054 12
NICUs 72 100 20.0040 to 20.00008 8
Regional
Adult ICUs 43 100 20.0162 to 0.0200 9 (2007–2008) and 10 (2008–2009)
PICUs 4 100 20.3745 to 0.0742 13
NICUs 6 100 20.2723 to 0.0145 12
ICU = intensive care unit; PICU = pediatric intensive care unit; NICU = neonatal intensive care unit; CVC-days = central venouscatheter-days.
doi:10.1371/journal.pone.0036582.t001
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small number of available pediatric and neonatal units that exist in
the Province of Quebec (5 and 7, respectively), and may partly
explain the better performance in some of the scenarios of the real
provincial database over our simulated one. However, as our
objective was to simulate a range of plausible CLABSI incidence
rates for adult, pediatric, and neonatal units, we were more
interested in generating rates with low bias relative to the original
SPIN rates, which was achieved, rather than with low variability.
Also, for random scenarios, we assumed that ICUs randomly
chose when to send data to the surveillance program, which may
not be completely true. Due to feasibility issues common to all
hospitals, it is possible that some ICUs will elect not to send data
during periods in which the risk of acquiring CLABSI is higher,
e.g., summer months, when nurse-patient ratio is reduced due to
vacations and/or when a high number of new and inexperienced
residents will be learning to insert CVCs in ICU patients, a
phenomenon that was not accounted for in our model.[19,20]
Finally, due to the different sizes and ICU population character-
istics of different regional and national surveillance programs, our
results may not be widely generalizable.
Nevertheless, our study makes an important contribution to
clarify the appropriateness of eliminating the continuous partic-
ipation requirement from multicentre CLABSI surveillance
programs. Although this strategy certainly decreases the financial
burden of surveillance and therefore facilitates the recruitment and
retention of participating hospitals, shortening the duration of
surveillance performed per year may negatively impact the validity
of the obtained results. To our knowledge, this is the first study
that evaluates the effect of different surveillance programs’
participation requirements on the validity of CLABSI incidence
rate benchmarks. Problems arising from the generation of biased
benchmarks are many, including the misleading of public health
officers and infection control teams, who will not accurately
identify priorities regarding CLABSI prevention and control.[21]
Also, with the increased popularity of public reporting of
healthcare-associated infection rates, biased benchmarks towards
higher CLABSI incidence rates may worry stakeholders and the
public about hospitals’ performance from a region or a
country.[22] Nevertheless, the major problem would arise from
biased benchmarks towards lower rates, which could lead to a false
belief in the success of the current infection control practices used
to prevent CLABSI in ICUs.
In conclusion, our simulation models showed that the elimina-
tion of a continuous participation requirement may be a suitable
alternative for large ICU CLABSI surveillance programs if data
submitted are randomly collected. However, minimum participa-
tion length should be based on the number of participating ICUs,
Figure 1. Graphic representation of the bias of the central line-associated bloodstream infection incidence rate estimates obtained
for the non-random scenarios.
doi:10.1371/journal.pone.0036582.g001
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decrease the risk of generating biased benchmarks, small
surveillance programs for CLABSI in ICUs such as regional ones,
should opt for continuous participation. Further research is needed
to determine the optimal length of participation for different
programs’ size.
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